Tag:

Abbott Laboratories

Latest Headlines

Latest Headlines

Western firms form band of brothers, but welcome others, in Asian medical device association

Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.

Diabetes device sales bounce back at Abbott with FreeStyle Libre

Diabetes care at Abbott Laboratories has returned to sales growth as ex-U.S. sales of its new FreeStyle Libre kick in and the impact of diabetes device reimbursement reductions dropped off the books. The continuous glucose monitor eliminates regular finger sticks and has surpassed the company's sales expectations.

NEA closes funds worth $3.1B after spate of Abbott med tech deals

New Enterprise Associates has closed a pair of funds totaling $3.15 billion to invest in information technology and healthcare companies. And while med tech may not loom particularly large for NEA, the firm does have roughly a couple of dozen active medical device portfolio companies.

Abbott puts one-third of its $6B Mylan stake on the block

Abbott Laboratories is selling off one-third of the stake in Mylan it acquired through last year's stock swap, a few weeks after Mylan wrapped up its $5.3 billion buyout of Abbott's portfolio of specialty and branded drugs.

Study: Newest drug-coated stents as effective as bypass surgery in coronary artery disease

The catheter-based insertion of one of the latest generation of drug-coated stents is just as effective as bypass surgery in treating coronary artery disease, according to a study in the latest issue of the New England Journal of Medicine. That was not the case with the prior generations of bare metal or first-generation drug-eluting stents.

Strong dollar expected to undercut medical device company earnings by 6% this year

As one of the country's large exporting industries, the medical device industry has been hit by the appreciation of the U.S. dollar, which makes exports more expensive and imports cheaper. 

To avoid becoming deal bait, Mylan CEO may have to make another big buy

It's been less than a week since Mylan completed its deal with Abbott, scooping up a large chunk of the Illinois company's overseas generics business. But CEO Heather Bresch is already hinting at another big transaction.

Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings

India's top drugmaker, Sun Pharmaceutical Industries, has agreed to buy GlaxoSmithKline's opiates business in Australia, placing it as one of three owners that control the crop and production in Tasmania that is the world's largest legal supplier of pharmaceutical-grade opiates for painkillers.

Israeli device seed firm Rainbow Medical raises $25M from Chinese investors

Rainbow Medical will open an office in Shanghai to help facilitate strategic deals as part of a $25 million cash infusion from investors in China. The firm is an Israeli-based seed investor and incubator specifically for medical device and medical technology startups.

Diabetes devices drag down Abbott in Q4, but 2015 growth expected on FreeStyle Libre in EU

Abbott Laboratories' sales of medical devices slipped by 3.9% to $1.4 billion in the fourth quarter of 2014 over the same period a year earlier. The company is looking to gain traction in medical devices with its entrance into the electrophysiology market with the December completion of its Topera acquisition.